WTO TRIPS Council (October 2017): India asks EU, Malaysia to share details of their respective compulsory licenses

On Friday, 20 October 2017, India delivered the following intervention on compulsory licensing. India briefly recounted the experiences of Brazil, South Africa, and Thailand in using compulsory licensing to secure access to ARVs.

Continue Reading

8 November 2016 – TRIPS Council – India’s intervention on the Paragraph 6 Mechanism

On 8 November 2016, India delivered the following statement on Review under Paragraph 8 of the Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health.

India’s Interventions at the TRIPS Council meeting (08-09 November 2016)

Agenda Item 7: Review under Paragraph 8 of the Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health

Continue Reading

9 November 2016 – WTO TRIPS Council – India’s intervention on the Report of the UN High-Level Panel on Access to Medicines

On Wednesday, 9 November 2016, India delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.

Agenda item 13: the United Nations Secretary-General’s High Level Panel Report on Access to Medicines

Statement by India.

Thank you Chairman.

At the outset, I would like to thank delegations of Brazil, China and South Africa who are also co-sponsors of this agenda item.

Continue Reading

17 WTO Members (Brazil, China, India, Russia) submit draft Ministerial Decision on Non-Violation and Situation Complaints

On 24 July 2015, 17 Members of the World Trade Organization (WTO) tabled a draft Ministerial decision (published by the WTO secretariat on 29 July 2015) on “Non-violation and situation complaints” for “consideration at the 10th Ministerial Conference of the WTO” (Source: IP/C/W/607). The 10th Ministerial Conference of the WTO will take place in Nairobi from 15 December 2015 to 18 December 2015. Continue Reading

67th WHA Side Event on Innovation and Access for Middle-Income Countries, Wednesday 21 May 2014

This Wednesday 21 May 2014, Knowledge Ecology International (KEI), Civil Society Coalition, Medecins Sans Frontieres (MSF), Oxfam, Health Action International (HAI) and Treatment Action Group (TAG) will host a side event at the WHA on, “Innovation and Access to Medicines and Vaccines: Emerging Challenges and Opportunities for Middle-Income Countries.”

Continue Reading

Colombian Submission to the WHO IGWG negotiation favors drug company positions on IP

By resolution WHA 59.24, the WHO’s Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) has the goal of producing a Global Strategy and Plan of Action that will implement the CIPIH report recommendations and “secure an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries, proposing cle Continue Reading

KEI Letter to Thailand Prime Minister and Health Minister, regarding compulsory licensing decisions

His Excellency Mr. Samak Sundaravej Prime Minister Government House Nakornpratom Rd. Dusit, Bangkok Thailand 10300 His Excellency Mr. Chaiya Sasomsap Minister of Public Health Tiwanont Rd. Talad Kwan District Nontaburi Province 11000 Thailand March 4, 2008 Re: Thailand Compulsory Licenses… Continue Reading

Thailand’s Compulsory Licensing Controversy

Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel).  The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US… Continue Reading

Notes from March 16th 2007 U.S. Capitol Briefing on Thailand’s Compulsory Licenses

On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading